NextCure seeks Delaware court validation of 2025 reverse split tied to Avere merger

NextCure, Inc.

NextCure filed a Section 205 petition on Sept. 14, 2026, in Delaware Court of Chancery seeking validation of its 1:12 reverse split filed July 10, 2025.
The 2025 reverse split drew 18,166,577 votes for, 2,028,946 against and 6,613 abstentions; 64.76% of outstanding shares backed it, short of the 66 2/3% supermajority.
The Delaware Court of Chancery scheduled a hearing for Nov. 6, 2026, at 3:00 p.m. ET; stockholder opposition submissions are due by Oct. 27, 2026, to the Register in Chancery.
NextCure plans a 2026 reverse split under the supermajority standard tied to its Avere Therapeutics combination; failure could delay or block that merger.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.